<DOC>
	<DOCNO>NCT02644889</DOCNO>
	<brief_summary>This study design order detect EGFR mutation abundance tissue concentration plasma Advanced Non-small Cell Lung Cancer treatment Tyrosine Kinase Inhibitor ( TKI ) .Through experiment investigator aim evaluate feasibility plasma EGFR detection evaluate correlation EGFR mutation prognosis .</brief_summary>
	<brief_title>EGFR Mutation Detection From Advanced NSCLC Patient Tissue Plasma EGFR-TKI Treatment</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Age old 18 year 75 year Histologically cytologically proven nonsmall Cell Lung Cancer Clinical stage Ⅲ ~ Ⅳ Not receive antitumor treatment Eastern cooperative oncology group performance status ( ECOG PS ) =1~2 Estimated survival time 3 month EGFRTKI treatment firstline secondline Voluntary participate clinical trial sign consent form Patients receive EGFRTKI therapy study With malignancy history recent 5 year study Pregnancy breast feed phase Inadequate sample test Followup compliance poor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Epidermal growth factor receptor ( EGFR )</keyword>
	<keyword>NSCLC</keyword>
</DOC>